39 research outputs found
Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice
Epidermal cell-specific quantitation of dopa decarboxylase mRNA inDrosophila by competitive RT-PCR: An effect ofBroad-Complex mutants
In women, no significant variances of calculated free testosterone (cFT) are observed when a fixed value of albumin (Alb: 4.3 g/dL) is used instead of measured albumin values
Passion : does one scale fit all? : construct validity of two-factor passion scale and psychometric invariance over different activities and languages
The Passion Scale, based on the dualistic model of passion, measures 2 distinct types of passion: Harmonious and obsessive passions are predictive of adaptive and less adaptive outcomes, respectively. In a substantive-methodological synergy, we evaluate the construct validity (factor structure, reliability, convergent and discriminant validity) of Passion Scale responses (N = 3,571). The exploratory structural equation model fit to the data was substantially better than the confirmatory factor analysis solution, and resulted in better differentiated (less correlated) factors. Results from a 13-model taxonomy of measurement invariance supported complete invariance (factor loadings, factor correlations, item uniquenesses, item intercepts, and latent means) over language (French vs. English; the instrument was originally devised in French, then translated into English) and gender. Strong measurement partial invariance over 5 passion activity groups (leisure, sport, social, work, education) indicates that the same set of items is appropriate for assessing passion across a wide variety of activities-a previously untested, implicit assumption that greatly enhances practical utility. Support was found for the convergent and discriminant validity of the harmonious and obsessive passion scales, based on a set of validity correlates: life satisfaction, rumination, conflict, time investment, activity liking and valuation, and perceiving the activity as a passion
The role of unaffiliated bankers on conditional conservatism: Evidence from IFRS information shock
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for The Evaluation and Treatment of Male Sexual Dysfunction: a Couple’s Problem–2003 Update
The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease
The Princeton Consensus (Expert Panel) Conference is a multispecialty collaborative tradition dedicated to optimizing sexual function and preserving cardiovascular health. The third Princeton Consensus met November 8 to 10, 2010, and had 2 primary objectives. The first objective focused on the evaluation and management of cardiovascular risk in men with erectile dysfunction (ED) and no known cardiovascular disease (CVD), with particular emphasis on identification of men with ED who may require additional cardiologic work-up. The second objective focused on reevaluation and modification of previous recommendations for evaluation of cardiac risk associated with sexual activity in men with known CVD. The Panel's recommendations build on those developed during the first and second Princeton Consensus Conferences, first emphasizing the use of exercise ability and stress testing to ensure that each man's cardiovascular health is consistent with the physical demands of sexual activity before prescribing treatment for ED, and second highlighting the link between ED and CVD, which may be asymptomatic and may benefit from cardiovascular risk reductio
All men with vasculogenic erectile dysfunction require a cardiovascular workup.
An association between erectile dysfunction and cardiovascular disease has long been recognized, and studies suggest that erectile dysfunction is an independent marker of cardiovascular disease risk. Therefore, assessment and management of erectile dysfunction may help identify and reduce the risk of future cardiovascular events, particularly in younger men. The initial erectile dysfunction evaluation should distinguish between predominantly vasculogenic erectile dysfunction and erectile dysfunction of other etiologies. For men believed to have predominantly vasculogenic erectile dysfunction, we recommend that initial cardiovascular risk stratification be based on the Framingham Risk Score. Management of men with erectile dysfunction who are at low risk for cardiovascular disease should focus on risk-factor control; men at high risk, including those with cardiovascular symptoms, should be referred to a cardiologist. Intermediate-risk men should undergo noninvasive evaluation for subclinical atherosclerosis. A growing body of evidence supports the use of emerging prognostic markers to further understand cardiovascular risk in men with erectile dysfunction, but few markers have been prospectively evaluated in this population. In conclusion, we support cardiovascular risk stratification and risk-factor management in all men with vasculogenic erectile dysfunction
Diagnosis and Treatment of Erectile Dysfunction for Reduction of Cardiovascular Risk
Purpose: We established erectile dysfunction as an often neglected but
valuable marker of cardiovascular risk, particularly in younger men and
men with diabetes. We also reviewed evidence that lifestyle change,
combined with informed prescribing of pharmacotherapies used to mitigate
cardiovascular risk, can improve overall vascular health and sexual
functioning in men with erectile dysfunction.
Materials and Methods: We performed a PubMed (R) search for articles and
guidelines pertinent to relationships between erectile dysfunction and
cardiovascular disease, cardiovascular and all cause mortality, and
pharmacotherapies for dyslipidemia and hypertension. The clinical
guidance presented incorporates the current literature and the expertise
of the multispecialty investigator group.
Results: Numerous cardiovascular risk assessment tools exist but risk
stratification remains challenging, particularly in patients at low or
intermediate short-term risk. Erectile dysfunction has a predictive
value for cardiovascular events that is comparable to or better than
that of traditional risk factors. Interventional studies support
lifestyle changes as a means of improving overall vascular health as
well as sexual functioning. Statins, diuretics, beta-blockers and
renin-angiotensin system modifiers may positively or negatively affect
erectile function. Furthermore, the phosphodiesterase type 5 inhibitors
used to treat erectile dysfunction may have systemic vascular benefits.
Conclusions: Erectile dysfunction treatment should be considered
secondary to decreasing cardiovascular risk. However, informed
prescribing may prevent worsening sexual function in men receiving
pharmacotherapy for dyslipidemia and hypertension. As the first point of
medical contact for men with erectile dysfunction symptoms, the primary
care physician or urologist has a unique opportunity to identify those
who require early intervention to prevent cardiovascular disease